Corning Jerry releases the latest data on KN026 in combination with KN046 for the treatment of first-line HER2-positive gastric/gastroesophageal joint cancer

As of January 30, 2022, a total of 31 patients with HER2-positive locally advanced unresectable or metastatic gastric/gastroesophageal junction cancer (GC/GEJ) who had not previously received systematic treatment were enrolled in the group, and 27 patients received at least one tumor evaluation: objective response rate (ORR) was as high as 77.

A phase III critical clinical study of KN026 in combination with KN046 for HER2-positive locally progressive unresectable or metastatic gastric/gastroesophageal junction cancer who have not previously received systematic treatment is about to start

September 14, 2022, Suzhou, China – Corning Jereh Biopharma (stock code: 9966.

Preliminary efficacy and safety results of KN026 in conjunction with KN046 in the treatment of HER2-positive gastric/gastroesophageal joint carcinoma without prior systematic therapy in a Phase II clinical study

Poster number: 1210P First author: Professor Shen Lin Beijing Cancer Hospital

As of January 30, 2022, the study enrolled 31 patients with HER2-positive locally advanced unresectable or metastatic gastric/gastroesophageal joint cancer who

Twenty-seven patients were assessed for effectiveness with objective response rates (ORRs) as high as 77.

In terms of safety, the most common treatment-related adverse events (TRAEs) were diarrhea (32.

About KN026KN026 is a HER2 bispecific antibody developed by Corning Jereh using Fc heterodimer platform technology (CRIB) with independent intellectual property rights, which can simultaneously bind to two non-overlapping epitopes of HER2, resulting in HER2 signal blockade, which is better than the combined effect of trastuzumab and patuzumab, such as showing higher affinity, and has a good tumor inhibition effect
in HER2-positive tumor cell lines.

At the same time, KN026 also has an inhibitory effect
on low-expressing tumors in HER2 and trastuzumab resistant cell lines.
KN026 has been approved by the State Drug Administration of China (NMPA) and the US Food and Drug Administration (FDA) in 2018, and is currently conducting a number of clinical trials at different stages in China and the United States, with indications including breast cancer, gastric cancer/gastroesophageal junction cancer, etc.
, KN026 combined chemotherapy, KN026 combined with KN046 and KN046 without chemotherapy for
gastric cancer two registered clinical studies are underway.

The trial results show that KN026 has good efficacy and safety, and still shows significant antitumor activity
in patients with HER2-positive breast cancer who have progressed after multi-line anti-HER2 therapy.
About KN046KN046 is a PD-L1/CTLA-4 bispecific antibody developed by Corning Jerehry with independent intellectual property rights
.

KN046 innovative design includes: the fusion composition of CTLA-4 and PD-L1 single-domain antibody with different mechanisms; It can target the tumor microenvironment enriched in PD-L1 high expression and clear the Treg
that inhibits tumor immunity.
KN046 has conducted more than 20 clinical trials at different stages in Australia, the United States and China, covering more than 10 tumors such as non-small cell lung cancer, pancreatic cancer, thymic cancer, liver cancer, esophageal squamous cell carcinoma, and triple-yin breast cancer, and the results show that patients have the advantage of
survival benefits.

Based on the results of clinical trials obtained in Australia and China, the U.
S.
FDA approved KN046 to enter a phase II clinical trial directly in the United States, and in September 2020 granted KN046 orphan drug qualification
for the treatment of thymic epithelial tumors.

At present, four registered clinical trials of KN046 are underway, among which the interim analysis of the phase III clinical study of KN046 combined with chemotherapy for the first-line treatment of non-small cell lung cancer has successfully reached the predetermined PFS endpoint
.
About Corning Jerry Corning Jereh Biopharma focuses on the development, manufacture, and commercialization of innovative anti-tumor drugs
.

On December 12, 2019, the Company was listed on the Main Board of the Hong Kong Stock Exchange under the stock code: 9966
.
Corning Jereh Biopharma has a full-industry chain discovery, R&D and manufacturing platform
for bispecific antibody and protein engineering.

The company's highly differentiated product line consists of new anti-tumor drugs such as monoclonal antibodies, bispecific antibodies and antibody conjugates
.

Six of these products are in Phase I to III clinical trials
in China, the United States, Japan and Australia.

In November 2021, Envida ^® (Envolizumab Injection) was officially approved for marketing in China for the treatment
of adult patients with advanced solid tumors who are highly unstable or metastatic microsatellites (MSI-H) or mismatched repair genodefective type (dMMR).
The company has a number of technology platforms with independent intellectual property rights, such as heterodimer and mixed antibodies, and large-scale production capacity that meets the cGMP standards of China, the United States and the European Union, and has passed the complete quality system
including the EU QP audit.

The company is committed to building an international leading and multi-dimensional drug development and industrialization platform, focusing on multifunctional biomacromolecule new drugs to benefit patients in China and around the
world.

Welcome to the company's website: www.
alphamabonc.
com